Your gift is 100% tax deductible.
Key Statistics for Basal Cell Carcinomas
Learn about key statistics for basal cell carcinomas, including how common they are, who is most affected, and the outlook for those with a diagnosis.
How common is basal cell carcinoma?
Skin cancers are by far the most common of all types of cancer in the United States. Most skin cancers are basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs). About 8 out of 10 skin cancers are BCCs.
According to one estimate, about 5.4 million BCCs and SCCs are diagnosed each year in the US, occurring in about 3.3 million people, as some people have more than one.
However, the exact number of people in the US who develop or die from BCCs each year isn’t known because BCCs are not reported to and tracked by cancer registries.
The number of these cancers has been increasing for many years. This is probably from a combination of better skin cancer detection, people getting more sun exposure, and people living longer.
Who gets basal cell carcinoma?
Anyone can get BCC, but the risk goes up as people get older. These cancers are also more common among men and among people with lighter skin tones. To learn more, see Causes, Risk Factors, and Prevention of Basal Cell Carcinoma .
What is the outlook for those with basal cell carcinomas?
Although basal cell carcinomas are common, deaths from these cancers are very rare. These cancers tend to grow slowly, and they rarely spread to other parts of the body.
BCCs can still cause serious problems if they’re not treated, as they can grow into nearby bones or other tissues beneath the skin.
Most people who die from these cancers are older and might not have seen a doctor until the cancer had already grown quite large or had spread. Those with suppressed immune systems, such as people who have had organ transplants, are also more likely to die from BCC.
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Aasi SZ. Treatment and prognosis of basal cell carcinoma at low risk of recurrence. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/treatment-and-prognosis-of-basal-cell-carcinoma-at-low-risk-of-recurrence on June 1, 2026.
Aasi SZ, Hong AM. Treatment of basal cell carcinomas at high risk for recurrence. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/treatment-of-basal-cell-carcinomas-at-high-risk-for-recurrence on June 1, 2026.
American Cancer Society. Facts & Figures 2026. American Cancer Society. Atlanta, Ga. 2026.
Rogers HW, Weinstock MA, Feldman SR, et al. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015;151(10):1081-1086.
Wu PA. Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/basal-cell-carcinoma-epidemiology-pathogenesis-clinical-features-and-diagnosis on June 1, 2026.
Xu YG, Aylward JL, Swanson AM, et al. Chapter 67: Nonmelanoma Skin Cancers. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.
Last Revised: August 11, 2026
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


